The two projects cover a cGMP cell therapy cleanroom and a USP 797 and USP 800 compliant cleanroom
QleanAir, the provider of solutions for clean indoor air, has announced letters of intent from two major health systems in the US. The cleanrooms are planned to be used for a large home infusion centre and for a cell therapy research lab.
The letters of intent have a value of approximately $1.2m and $600,000 respectively, for a total of $1.8m. The two Letters of Intent are expected to turn into contracts and the order book during the autumn 2022. Both new cleanrooms are expected to complete in Q2 of 2023.
The first contract is with a major health system to provide a USP 797 and USP 800 compliant cleanroom. This cleanroom will be built in a new home infusion centre at a major health system in the US.
Whilst the second contract is with a second major health system in the US to provide a cGMP cell therapy research laboratory cleanroom. This cleanroom will be built in an existing space and house a BSL-2 clean space.
“Our team is excited to work closely with our customers’ teams to provide a cleanroom that is technologically advanced and provides a safe working space," said Zachary Douglas, President of QleanAir Scandinavia. "It’s amazing to get opportunities with organisations like these, who share our dedication to patient and employee safety.”
“At QleanAir, we are proud to deliver safe and healthy patient and working environments, and to gain new opportunities to be a part of important scientific work," added Christina Lindstedt, CEO QleanAir. "I am very pleased that we are extending our customer base and developing new partnerships by our US team."